Additionally, we found a higher degree of concordance in the urothelial carcinoma cohort as compared with the prostate cancer cohort with respect to HER2 expression between metastatic sites, especially in patients with HER2 3+ disease. This evidence concerns the gene ERBB2 and prostate carcinoma.